FDA notifies the Pomona, N.Y.-based generic drugs company Sept. 19 of its compliance with current Good Manufacturing Practices after inspections of Barr's Northvale, N.J. and Pomona facilities. Barr will now be able to receive approval for over 10 pending ANDAs and supplements for products not currently marketed. The company says it will bring back only those products that are economically significant. Barr undertook a revalidation program and has since reintroduced more than nine products under FDA validation requirements. The company had to suspend production of 24 products in February 1993 following litigation with FDA
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth